A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer

Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes with varying major pathological response (MPR) rates. MPR patients had elevated levels of FGFBP2<sup>+</sup> NK/NK-like T cells, memory B cells, or effector T cells, while non-MPR patients showed higher CCR8<sup>+</sup> Tregs. T cell clonal expansion analyses unveiled heterogeneity in non-MPR patients, marked by varying expansions of Tex-relevant cells and CCR8<sup>+</sup> Tregs. Precursor exhausted T cells (Texp cells) correlated with recurrence-free survival, identifying a patient subgroup with reduced recurrence risk despite lack of MPR. Our study dissects TIME heterogeneity in response to chemoimmunotherapy, offering insights for NSCLC management.

Authors

Institutions

Publication Details

Journal
Cell
Published
2025-03-27
DOI
https://doi.org/10.1016/j.cell.2025.03.018
Citations
71
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
74.22
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer

Yuxuan Sun, Deping Zhao, Xiangjie Li, Lishan Peng et al.
71 citations
Cell
Cancer Immunotherapy and Biomarkers
74.22
article

A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer

Yuxuan Sun, Deping Zhao, Xiangjie Li, Lishan Peng, Bolun Zhou, Zedao Liu, Sijin Cheng, Chang Zou, Minglei Yang, Qianqian Gao, Liang Zhao, Hui Peng, Yongjun Guo, Honghao Fu, Zhenlin Yang, Xiaoyan Liu, Zemin Zhang, Chang Liu, Guangjian Zhang, Zhigang Zhao, Wen‐Zhao Zhong, Zhigang Tian, Shugeng Gao, Wenjie Zhang, Yang Li, Lei Zhang, Yongjie Wang, Xiaowei Chen, Chao Zhang, Dingcheng Yi, Yi-Long Lung Cancer Wu, Li‐Xu Yan, Yufei Bo, Chen Chang, Ya‐Wen Chen, Qingyuan Cai, Qi Lu, Junqi Wu, Xueda Hu, Wei Tang, Xiaoshi Ma, Ben‐Yuan Jiang, Yang Qu, Guangyu Bai, Linnan Zhu, Shun He, Fengwei Tan, Long Xu, Hongtao Fan, Wanting Zhang, Yunlang She, Yu Zhang
article en
71 citations

Abstract

Anti-PD-(L)1 treatment is standard for non-small cell lung cancer (NSCLC), but patients show variable responses to the same regimen. The tumor immune microenvironment (TIME) is associated with immunotherapy response, yet the heterogeneous underlying therapeutic outcomes remain underexplored. We applied single-cell RNA and TCR sequencing (scRNA/TCR-seq) to analyze surgical tumor samples from 234 NSCLC patients post-neoadjuvant chemo-immunotherapy. Analyses revealed five distinct TIME subtypes with varying major pathological response (MPR) rates. MPR patients had elevated levels of FGFBP2<sup>+</sup> NK/NK-like T cells, memory B cells, or effector T cells, while non-MPR patients showed higher CCR8<sup>+</sup> Tregs. T cell clonal expansion analyses unveiled heterogeneity in non-MPR patients, marked by varying expansions of Tex-relevant cells and CCR8<sup>+</sup> Tregs. Precursor exhausted T cells (Texp cells) correlated with recurrence-free survival, identifying a patient subgroup with reduced recurrence risk despite lack of MPR. Our study dissects TIME heterogeneity in response to chemoimmunotherapy, offering insights for NSCLC management.

CellVol. 188(11)
Qingdao University (CN), Tongji University (CN), University of Science and Technology of China (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Ningbo No. 2 Hospital (CN), Shenzhen Bay Laboratory (CN), Affiliated Hospital of Qingdao University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), Shanghai Pulmonary Hospital (CN), Henan Cancer Hospital (CN), Guangdong Academy of Medical Sciences (CN), Analytical Biosciences (China) (CN), Guangdong Provincial People's Hospital (CN), First Affiliated Hospital of Zhengzhou University (CN)
Good health and well-being
Openalex Percentile: Top 0%
Cancer Immunotherapy and Biomarkers
74.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.